Search
Discussing the MIRASOL ovarian cancer data with Immunogen at #ASCO23
- blonca9
- Jun 4, 2023
- 1 min read
Updated: Jun 15, 2023
Immunogen CEO Mark Enyedy describes Elahere’s MIRASOL trial result and what it means for ovarian cancer and ADCs.
Also look for unique social pages for BiotechTV U.
Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.